Prediction of adverse clinical outcomes in patients with coronavirus disease 2019

OBJECTIVE: This study aims to investigate blood and biochemical laboratory findings in patients with coronavirus disease (COVID‐19) and analyze the potential predictors of poor outcome in patients with COVID‐19. METHODS: The clinical, laboratory, and outcome data of 87 patients with COVID‐19 were collected and retrospectively analyzed. Only data collected at the time of admission were used in the analysis for predictors of poor outcome. These patients were divided into two groups: the adverse prognosis group (36 patients) and the non‐adverse prognosis group (51 patients). The adverse prognosis of COVID‐19 patients was defined as admission to the intensive care unit or death. RESULTS: On the univariate analysis, age, white blood cell (WBC) count, neutrophil counts, lymphocytes count, neutrophils‐to‐lymphocytes ratio (NLR), interleukin‐6, albumin‐to‐globulin ratio (AGR), albumin, lactate dehydrogenase, glutamyl transpeptidase, and blood glucose were found to be the significant predictors. On the multivariate analysis, the predictors of poor outcome of patients with COVID‐19 were NLR (OR = 2.741, [95% CI = 1.02 ~ 7.35], P = .045) and IL‐6 (OR = 1.405, [95% CI = 1.04 ~ 1.89, P = .025]). The receiver operating characteristic (ROC) curve revealed that the AUC of NLR, interleukin‐6, pneumonia severity index (PSI) score, and Confusion‐Urea‐Respiratory Rate‐Blood pressure‐65 (CURB‐65) score were 0.883, 0.852, 0.824, and 0.782, respectively. CONCLUSION: High interleukin‐6 (6 pg/mL, cuff value) and NLR (4.48, cuff value) can be used to predict poor outcomes in patients with COVID‐19 on admission, thus can serve as a beneficial tool for timely identifying COVID‐19 patients prone to poor outcome and reduce patient mortality through early intervention.